Why the study?
Does intravenous streptokinase improve outcomes in patients with acute myocardial infarction?
Does intravenous streptokinase improve outcomes in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
This review highlights that intravenous streptokinase in acute myocardial infarction provides earlier chest pain relief and reduces 6-month mortality, particularly in patients with higher disease severity.
Experience with intravenous streptokinase in acute myocardial infarction gained in the past 20 years may be helpful for future developments. Trials have shown that in streptokinase-treated patients, cardiac enzyme activities reached an earlier and higher maximum, the total peripheral resistance was reduced, relief of chest pain occurred earlier and the reduction of 6-month mortality was more pronounced if patients with a higher severity of the disease were treated.
No takes yet. Share an insight, caveat, or question.
J.C.W. van de Loo (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: